On Thursday, Stockholm-based Neko Health, a preventative healthcare technology company, announced that it has secured $260M (approximately €250M) in a Series B funding round led by Lightspeed Venture Partners.
With this funding round, Neko Health is currently valued at $1.8B (approximately €1.7B) post-money, reports TechCrunch.
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating innovations and trends in the Enterprise, Consumer, and Health sectors. The company has backed hundreds of entrepreneurs and helped build more than 400 companies globally.
BejulSomaia, Global Partner, Lightspeed Venture Partners, says, “After meeting Hjalmar, Daniel, and their team, it was clear Neko Health wasn’t just building another healthcare company – they were fundamentally rethinking how we approach prevention. Neko combines breakthrough technology with meticulous attention to detail in everything from its scanning technology to the patient experience. With a long waitlist and a clear path to international expansion, we believe comprehensive preventive care can be both accessible and scalable.”
Other investors, including General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico, also participate in the round.
As part of this funding round, BejulSomaia, Partner at Lightspeed Venture Partners will join the Board of Directors at Neko Health.
The announcement comes over a year and a half after raising €60M in a Series A round of funding.
As per the company’s claims, the Swedish company has completed 10,000 scans across Stockholm and London, nearly two years after the launch.
On average, 80 per cent of members book and prepay a scan for the following year at the end of their appointment.
Demand remains high, with the global waiting list totalling more than 100,000.
As a result, the company is building out capacity with further locations and new regions.
Neko Health: Building a better healthcare
Founded in 2018 by Hjalmar Nilsonne and Daniel Ek, Neko Health aims to develop a healthcare system that can help individuals maintain their health via early identification and preventative actions.
The company has developed a new medical scanning technology concept for broad and non-invasive health data collection that is fast, convenient and affordable.
The company’s non-invasive Scan costs £299 and maps millions of health data points on the body – both inside and out – in just a few minutes.
It checks moles and marks across the body, symptoms of metabolic syndrome, and risk factors for stroke and heart attack, along with blood sugar levels to assess pre-diabetes risk.
For example, it can detect changes in the skin as little as 0.2 millimetres because of its utilisation of over 70 sensors and 50 million data points collected in minutes.
With the use of current technology, clinicians should be able to identify diseases like skin problems, skin cancer, cardiovascular disease, diabetes, and other metabolic syndromes early.
The whole experience is complete in just under an hour, says the company.
Hjalmar Nilsonne, CEO and Co-Founder of Neko Health says, “We’re at the beginning of a big shift of the healthcare market, from reactive to proactive, driven both by technological advancements and growing consumer demand. This round of financing accelerates Neko’s global expansion of locations to include the US, as well as investments in breakthrough R&D. In the coming years Neko will continue to bring incredible innovations to the market to find and prevent disease before it has a chance to develop.”
The Neko Body Scan is currently available in London and Stockholm, with plans for further expansion in the coming months.
01
Upstream Festival is back for its sixth edition! 4 solid reasons to mark your calendar